MedPath

Volagidemab

Generic Name
Volagidemab
Drug Type
Biotech
CAS Number
1233956-13-2
Unique Ingredient Identifier
77JYS6UZ0M
Background

Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).

Clinical Trials
Related News

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

Phase 1
Recruiting
Conditions
Type 1 Diabetes
Interventions
First Posted Date
2023-01-25
Last Posted Date
2024-11-04
Lead Sponsor
University of California, San Diego
Target Recruit Count
24
Registration Number
NCT05696366
Locations
🇺🇸

UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Early Phase 1
Completed
Conditions
Glucose Tolerance Impaired
Insulin Sensitivity
Type 2 Diabetes
Interventions
Drug: Placebo Subcutaneous injection
First Posted Date
2021-10-26
Last Posted Date
2024-08-09
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
4
Registration Number
NCT05093517
Locations
🇺🇸

Texas Diabetes Institute, San Antonio, Texas, United States

Effects of GRA in Patients With Type 1

Phase 2
Active, not recruiting
Conditions
Type 1 Diabetes
Interventions
Drug: Placebo
First Posted Date
2021-03-03
Last Posted Date
2024-01-23
Lead Sponsor
University of California, San Diego
Target Recruit Count
30
Registration Number
NCT04779645
Locations
🇺🇸

UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Phase 1
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: Placebo
First Posted Date
2020-09-11
Last Posted Date
2023-01-23
Lead Sponsor
University of California, San Diego
Target Recruit Count
12
Registration Number
NCT04545411
Locations
🇺🇸

UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

Phase 1
Completed
Conditions
Type 1 Diabetes Mellitus
Interventions
First Posted Date
2019-04-18
Last Posted Date
2022-07-15
Lead Sponsor
University of California, San Diego
Target Recruit Count
4
Registration Number
NCT03919617
Locations
🇺🇸

UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy